Gene therapy for heart failure recovery trial
Part of Heart & circulation clinical trials.
This trial tests a gene therapy injected into the heart to help it recover after a previous heart attack. It may be an option for people with stable heart failure who are not eligible for standard procedures like stents or bypass surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 79 years old.
- You have heart failure caused by a past heart attack (ischemic heart disease).
- Your symptoms are class II or III (shortness of breath or fatigue with activity).
- Your heart's pumping ability (ejection fraction) is between 20% and 40%. This is measured by an MRI.
- You are not a candidate for stents (PCI) or bypass surgery (CABG).
- You have been on stable heart failure medications for at least 6 weeks.
- You do not have serious other heart diseases, like valve problems, or other organ issues like liver or kidney failure.
- You do not have an active infection, uncontrolled diabetes, or a history of recent stroke or heart attack.
- You agree to use birth control if needed and do not plan to become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether injecting special cells (HiCM-188) during bypass surgery can help improve heart function in people with advanced heart failure. The cells may help repair damaged heart tissue and improve your heart's ability to pump blood.
This trial tests a one-time gene therapy for people with heart failure who still have normal pumping strength (preserved ejection fraction). It aims to improve how heart cells handle calcium, which may help the heart relax better and ease symptoms.
This trial tests a treatment made from stem cells that are turned into heart muscle cells and injected directly into the heart. It is for people with advanced heart failure who are already on the best available medicines and who are scheduled to have bypass surgery.
This trial tests a gene therapy that may help rebuild muscle and improve blood vessel growth in people ages 35 to 75. It's designed for those with stable health conditions and no history of cancer, heart disease, blood clots, or diabetes.
This study tests an experimental gene therapy called ALXN2350 for people with dilated cardiomyopathy caused by a specific genetic change in the BAG3 gene. It aims to see if the therapy can improve heart function and slow disease progression.
This trial tests a gene therapy called XC001, given directly to the heart during bypass surgery, to help grow new blood vessels and improve blood flow to areas that cannot be fully fixed with surgery alone.
Hear when a new Heart Failure With Reduced Ejection Fraction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.